2. Academic Validation
  3. Afatinib boosts CAR-T cell antitumor therapeutic efficacy via metabolism and fate reprogramming

Afatinib boosts CAR-T cell antitumor therapeutic efficacy via metabolism and fate reprogramming

  • J Immunother Cancer. 2024 Nov 17;12(11):e009949. doi: 10.1136/jitc-2024-009949.
Yueyu Dai # 1 2,  Yue Liu # 2 3,  Lingna An 2 3,  Fangyuan Zhong 4,  Xi Zhang 5 3 6,  Shifeng Lou 7
Affiliations

Affiliations

  • 1 Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, Chongqing, China.
  • 2 Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, Chongqing, China.
  • 3 State Key Laboratory of Trauma and Chemical Poisoning, Chongqing Key Clinical Specialty, Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing, Chongqing, China.
  • 4 Department of Gynecology and Obstetrics, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
  • 5 Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, Chongqing, China 300326@hospital.cqmu.edu.cn zhangxxi@sina.com.
  • 6 Jinfeng Laboratory, Chongqing, Chongqing, China.
  • 7 Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, Chongqing, China 300326@hospital.cqmu.edu.cn zhangxxi@sina.com.
  • # Contributed equally.
PMID: 39551605 DOI: 10.1136/jitc-2024-009949
Abstract

Background: Chimeric antigen receptor T (CAR-T) cell therapy has been shown remarkable efficacy in the treatment of hematological malignancies in recent years. However, a considerable proportion of patients would experience tumor recurrence and deterioration. Insufficient CAR-T cell persistence is the major reason for relapse. Multiple strategies to enhance the long-term antitumor effects of CAR-T cells have been explored and developed. In this study, we focused on tyrosine kinase inhibitors (TKIs), which have emerged immunomodulatory potential besides direct tumoricidal effects.

Methods: Here, we screened 50 approved TKIs drugs and identified that afatinib (AFA) markedly enhanced the expressing of CD62L and inhibited Reactive Oxygen Species level in T cells. And the underlying mechanisms of AFA medicating T cells were explored by detecting signal transduction, and metabolism pattern. Furthermore, we co-cultured AFA with CAR-T cells during the preparation stage and multianalyses of differentiation characteristics, metabolic profiling, and RNA Sequencing revealed that AFA induce comprehensive metabolism remodeling and fate reprogramming. Based on it, we finally identified the antitumor efficacy of AFA-pretreatment CAR-T compared with negative-control CAR-T.

Results: We identified that AFA blocked the T-cell receptor (TCR) and phosphoinositide 3-kinase-protein kinase B-mechanistic target of rapamycin signaling pathways, induced metabolic reprogramming and modulated T-cell differentiation. When combined with CAR-T cells, AFA inhibited the exhaustion and enhanced the persistence and cytotoxicity. Our results revealed that the pretreatment of AFA enables to boost CAR-T cells with strong antitumor cytotoxicity in leukemia mouse model.

Conclusions: Our study systematically demonstrated that AFA pretreatment effectively enhanced CAR-T cells antitumor performance, which presents a novel optimization strategy for potent and durable CAR-T cell therapy.

Keywords

Adoptive cell therapy - ACT; Chimeric antigen receptor - CAR; Hematologic Malignancies.

Figures
Products
Inhibitors & Agonists
Other Products